r adult patients only:


Routine prophylaxis to reduce the frequency of bleeding episodes.


Detailed Important Risk Information

CONTRAINDICATIONS
VONVENDI is contrindicated in patients who have had life-threatening hypersensitivity reactions to VONVENDI or constituents of the product (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins).

WARNINGS AND PRECAUTIONS
Thromboembolic Events
Thromboembolic events have occurred with VONVENDI. These events can include disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke. Patients with known risk factors for thrombosis, including low ADAMTS13 levels are at a higher risk. Monitor patients for signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope. Institute prophylaxis measures against thromboembolism
=*=*=*=*=*=
当前为第6/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页